Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London open: Fed taper sparks 'Santa Rally' as stocks jump

Thu, 19th Dec 2013 08:17

- Fed cuts monthly bond buying to 75bn dollars- Commits to near-zero rates, depending on inflation- Pharma peers AstraZeneca, GSK making gainstechMARK 2,727.60 +1.12%FTSE 100 6,553.38 +0.94%FTSE 250 15,550.52 +1.20%UK markets opened around one per cent higher on Thursday morning in the aftermath of the Federal Reserve's decision to taper its quantitative easing programme, as investors welcomed the end to months of uncertainty."This should in turn remove much of the volatility that we have seen in the final quarter of 2013, gearing us up for a delayed but eagerly anticipated 'Santa Rally' to finish this year in a bang and kick off the next year in an upbeat fashion," said Market Strategist Ishaq Siddiqi from ETX Capital.The Federal Reserve announced on Wednesday night that it would scale back its monthly bond-buying programme from $85bn to $75bn and said it would make similar moderate reductions in the future subject to incoming economic data. The news sent both the Dow Jones Industrial Average and S&P 500 to new record highs on Wall Street.Policymakers predicted that the jobless rate - currently at 7% - would drop to around 6.5% by the end of 2014. However, they stressed that they would hold interest rates close to zero "well past the time that the unemployment rate declines below 6.5%, especially if projected inflation continues to run below the [FOMC's] 2% longer-run goal"."The action today is intended to keep the level of accommodation the same overall and to push the economy forward," said Chairman Ben Bernanke. "We are committed to doing what is necessary to getting inflation back to target."AstraZeneca jumps on BMS dealAstraZeneca was a high riser this morning after spending up to $4.1bn in Bristol-Myers Squibb's stake in their diabetes joint venture, giving the British company full ownership of intellectual property and global rights for a large portfolio of products.Fellow pharma group GlaxoSmithKline (GSK) also advanced after announcing yesterday evening that US regulators have approved Anoro Ellipta, its treatment for chronic obstructive pulmonary disease. Upside however was limited on the news that Denmark has approved the sale of a generic copy of GSK's biggest product, Advair.There were just a handful of fallers on the FTSE 100 early on, with mining peers Fresnillo and Randgold Resources among them as precious metals prices declined. Support services group Serco fell after warning that recent contract problems may hit its cash flow this year. However, it still said 2013 results were likely to meet market hopes.Financial stocks were mixed with RSA Insurance, Standard Chartered and HSBC trading lower, and Barclays, Resolution and Prudential among the best performers.FTSE 100 - RisersPetrofac Ltd. (PFC) 1,122.00p +3.03%BAE Systems (BA.) 446.20p +2.79%Resolution Ltd. (RSL) 335.90p +2.50%Hammerson (HMSO) 502.50p +2.49%Standard Life (SL.) 348.60p +2.44%Persimmon (PSN) 1,196.00p +2.40%Land Securities Group (LAND) 949.50p +2.32%WPP (WPP) 1,328.00p +2.31%ITV (ITV) 185.40p +2.26%Prudential (PRU) 1,299.00p +2.20%FTSE 100 - FallersRandgold Resources Ltd. (RRS) 3,820.00p -2.45%Fresnillo (FRES) 717.00p -1.38%Standard Chartered (STAN) 1,309.00p -0.76%HSBC Holdings (HSBA) 643.40p -0.76%RSA Insurance Group (RSA) 89.90p -0.72%United Utilities Group (UU.) 647.50p -0.46%Severn Trent (SVT) 1,674.00p -0.24%Sainsbury (J) (SBRY) 364.80p -0.08%Glencore Xstrata (GLEN) 306.50p -0.08%FTSE 250 - RisersRedrow (RDW) 308.00p +3.39%Close Brothers Group (CBG) 1,374.00p +3.31%Bovis Homes Group (BVS) 783.00p +2.96%Jupiter Fund Management (JUP) 377.30p +2.95%Supergroup (SGP) 1,401.00p +2.86%Henderson Group (HGG) 208.40p +2.86%Keller Group (KLR) 1,135.00p +2.81%Halfords Group (HFD) 451.60p +2.80%Shaftesbury (SHB) 613.50p +2.76%SEGRO (SGRO) 333.60p +2.71%FTSE 250 - FallersAfrican Barrick Gold (ABG) 155.00p -3.73%Serco Group (SRP) 437.50p -2.52%Polymetal International (POLY) 511.00p -1.26%Hochschild Mining (HOC) 125.10p -1.11%888 Holdings (888) 159.50p -0.93%BH Macro Ltd. EUR Shares (BHME) € 19.81 -0.90%Diploma (DPLM) 704.50p -0.77%Barr (A.G.) (BAG) 568.00p -0.61%Cable & Wireless Communications (CWC) 52.30p -0.57%NMC Health (NMC) 442.50p -0.56%BC
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.